Gansu Province Wuwei Tumor Hospital has been approved for its first provincial chief scientist project, led by Professor Ye Yancheng to tackle radiation-resistant tumors with carbon ion therapy. Leveraging 30 major research platforms and 9 globally advanced technologies, the hospital is developing a "China Solution" to provide new hope for precise treatment of refractory cancers such as pancreatic cancer and glioblastoma.

In accordance with the requirements of "Notice on Carrying out the Evaluation and Commendation Work of the Ninth Gansu Provincial People's Government Quality Award" (Gan Shijian Fa [2025] No. 72) issued by Gansu Provincial Market Supervision Administration and Gansu Provincial Human Resources and Social Security Department, after the declaration of the Heavy Ion Center and qualification review and other procedures, the center discussed and agreed that the Heavy Ion Center can participate in the evaluation of the Ninth Gansu Provincial People's Government Quality Award. It is now publicized as follows:

Frequently Asked Questions (FAQs) for Radiotherapy Patients

On May 27, Professor Feng Qinfu, a national chief expert, visited the Heavy Ion Center of Gansu Province Wuwei Tumor Hospital to provide clinical guidance. He went deep into the front lines of clinical practice, conducted ward rounds and discussions on difficult cases, promoted further upgrades in radiotherapy technology, and provided precise diagnostic and treatment guarantees for chest tumor patients in the northwest region.

Explore the "multimodal integration" cocktail therapy, scientifically combining chemotherapy, targeted therapy, immunotherapy, and anti-angiogenic drugs like mixing cocktails to customize personalized treatment plans for cancer patients. Professor Pan Ming's team at Lanzhou Campus of Gansu Wutai Cancer Hospital leverages MICM precision diagnostics and laminar flow wards to provide refined diagnosis and treatment for lung cancer, hematologic diseases, and more, improving survival rates and quality of life.

The Lanzhou campus of Gansu Wuhui Cancer Hospital has launched a clinical study on radical carbon ion radiotherapy for breast cancer, with patients receiving treatment at zero out-of-pocket cost. This project aims to align with international standards by using precise carbon ion radiotherapy to achieve surgery-free and breast-conserving outcomes. Led by top experts including Shen Wenjiang and Wang Junjie, the Phase II clinical trial will recruit 42 eligible breast cancer patients.

The Lanzhou campus of Gansu Provincial Wuwei Tumor Hospital has launched a clinical study on zero out-of-pocket expenses for heavy ion therapy in high-grade gliomas. The Phase II trial combining carbon ion and photon radiotherapy is recruiting 23 patients, covering approximately 156,000 yuan in treatment costs. Aimed at improving survival rates, eligible individuals are welcome to register for consultation.

With the continuous deepening of population aging in China, the incidence rate of benign prostatic hyperplasia (BPH) among middle-aged and elderly men has been rising annually, becoming one of the prevalent chronic diseases that significantly impair the daily quality of life for men.

The Lanzhou Campus of Gansu Provincial Wuwei Cancer Hospital has launched a clinical study on zero out-of-pocket carbon ion radiotherapy for solid tumors in patients aged 80 and above, opening recruitment nationwide. The project aims to evaluate the safety and efficacy in elderly patients, waiving all treatment costs, with precision diagnosis and treatment plans provided by a top-tier expert team.

The Lanzhou campus of Gansu Provincial Wuwei Tumor Hospital has launched a Phase II clinical study on curative carbon ion radiotherapy for nasopharyngeal carcinoma, recruiting patients nationwide with cT1-3N0-2M0 staging. Enrolled participants will receive free treatment fees for heavy ion therapy, with treatment plans formulated by a top-tier expert team led by Professor Shen Wenjiang, ensuring precision and efficiency. For more details, please consult Director Zhang Yingdong.